I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site

Acute Ischemic Stroke

What's new

Sign up or login to unlock the full suite of MEDICALLY features

Feb 6 / Roche and Genentech
Factors Impacting Racial and Ethnic Disparities in the Use of Intravenous Thrombolytics in a Large Western US Healthcare System
This retrospective analysis of patients with ischemic stroke evaluated racial, ethnic and geographic differences in administration of intravenous thrombolytics. Patient characteristics and treatment outcomes were derived from a system-wide stroke registry comprising 40 hospitals in the Western US.

Sign up or login to unlock the full suite of MEDICALLY features

Feb 6 / Roche and Genentech
Quantifying the Health Equity Impact of Tenecteplase for Acute Ischemic Stroke in the United States: a Distributional Cost-Effectiveness Analysis
This distributional cost-effective analysis (DCEA) evaluated how tenecteplase within 4.5 hours of AIS symptom onset impacts overall health and health disparities in ischemic stroke considering race and ethnicity and geography in the US.

Sign up or login to unlock the full suite of MEDICALLY features

May 15 / Roche and Genentech
THE HEALTH EQUITY IMPACT OF ALTEPLASE FOR ACUTE ISCHEMIC STROKE IN THE UNITED STATES: A DISTRIBUTIONAL COST-EFFECTIVENESS ANALYSIS
The purpose of this study was to perform an equity analysis using a distributional cost-effectiveness analysis framework to evaluate how alteplase impacts overall health (efficiency) and health disparities (equity) in acute ischemic stroke considering race, ethnicity and geography and to explore the impact of health system factors to identify and prioritize policy and public health interventions that could lead to the largest positive impacts on health equity in the US.

Sign up or login to unlock the full suite of MEDICALLY features

May 15 / Roche and Genentech
Disease Burden of Acute Ischemic Stroke in Underserved Populations Across the US in 2022
This secondary analysis examined disparities in disease burden of acute ischemic stroke by race, ethnicity, sex and region in the US.

Sign up or login to unlock the full suite of MEDICALLY features

May 15 / Roche and Genentech
Secondary Analyses from the TIMELESS Trial
The purpose of this post hoc analysis is to assess treatment efficacy in patients with acute ischemic stroke treated with tenecteplase in the TIMELESS trial grouped by occlusion location (M1/M2), time between tenecteplase administration and clot contact, and symptomatic intracranial hemorrhage/parenchymal hematoma type 2.

Sign up or login to unlock the full suite of MEDICALLY features

May 6 / Roche and Genentech
Health Equity Impacts of Alteplase for Ischemic Stroke in the United States: A Distributional Cost-Effectiveness Analysis
The purpose of this analysis was to highlight disparities in acute ischemic stroke (AIS) across the patient journey by examining the impact of thrombolytic use across population subgroups (including vulnerable populations), evaluate the impact of thrombolytic use (with alteplase) on overall health (efficiency) and health disparities (equity), and to estimate the impact of health system factors on equity outcomes.

Ask a question or share feedback